Development of an Artificial Intelligence Model for Optimising Therapy in Gliomas Gliomas

Last updated: September 26, 2024
Sponsor: Centro di Riferimento Oncologico - Aviano
Overall Status: Active - Recruiting

Phase

N/A

Condition

Astrocytoma

Neurofibromatosis

Brain Cancer

Treatment

N/A

Clinical Study ID

NCT06620055
CRO-2023-40
  • Ages > 18
  • All Genders

Study Summary

Artificial intelligence (AI) undoubtedly represents the main tool currently available in the definition of complex algorithms and its use in the medical field is becoming increasingly strategic.As reported in the literature, it is increasingly difficult to find new therapeutic strategies for neoplasms, especially neurological ones. Molecular characterisation is therefore increasingly essential, as is the use of new predictive methods.

With this in mind, the aim of this study is to assess, by means of AI algorithms applied to genomic data, in what percentage molecular alterations are susceptible to potential drug therapies, compared to the literature data that does not consider AI algorithms for this purpose.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patients with a histopathological diagnosis of glioma for whom it is possible tohave cryopreserved or fixed in formalin and embedded in paraffin biologicalmaterial. Specimens may result from incisional biopsy and/or surgical resectionand/or blood. Whole blood is taken for germinal analysis;

  2. Age >=18 years;

  3. Patients must understand and provide written informed consent;

  4. Life expectancy >3 months;

  5. Presence of biological material from resection and blood considered sufficient byquality and quantity to proceed to molecular characterisation in the opinion of theInvestigator Principal Investigator;

  6. Presence of available and accessible clinical and histopathological data.

Exclusion

Exclusion Criteria:

  1. Refusal of informed consent;

  2. Uncooperative patients;

  3. Presence of other neoplastic diseases in the last 5 years;

  4. Pregnant and/or breastfeeding women

Study Design

Total Participants: 164
Study Start date:
November 16, 2023
Estimated Completion Date:
November 16, 2028

Study Description

Artificial intelligence (AI) undoubtedly represents the main tool currently available in the definition of complex algorithms and its use in the medical field is becoming increasingly strategic.As reported in the literature, it is increasingly difficult to find new therapeutic strategies for neoplasms, especially neurological ones. Molecular characterisation is therefore increasingly essential, as is the use of new predictive methods.

With this in mind, the aim of this study is to assess, by means of AI algorithms applied to genomic data, in what percentage molecular alterations are susceptible to potential drug therapies, compared to the literature data that does not consider AI algorithms for this purpose.

Connect with a study center

  • Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS

    Aviano, Pordenone 33081
    Italy

    Active - Recruiting

  • IOV

    Padova,
    Italy

    Active - Recruiting

  • Azienda Sanitaria Universitaria Friuli Centrale (ASUFC

    Udine, 33100
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.